MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
Histopathology 2018 October 17 [Link]
Kai Y1,2, Amatya VJ1, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y
The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers to definitively diagnose epithelioid mesothelioma. The aim of this study was to search for a novel negative marker of epithelioid mesothelioma.
MATERIALS AND METHODS:
We immunohistochemically studied the applicability of mucin 21 (MUC21), which was identified in our previous study, as a novel, negative diagnostic marker for epithelioid mesothelioma. Seventy epithelioid mesothelioma and 70 lung adenocarcinoma cases were investigated for the expression of MUC21, along with other previously reported markers, by immunohistochemistry.
MUC21 was expressed in only 2 of the 70 (3%) epithelioid mesothelioma cases, compared to 67 of the 70 (96%) lung adenocarcinoma cases. The sensitivity, specificity, and accuracy of negative MUC21 expression to differentiate epithelioid mesothelioma from lung adenocarcinoma were 97%, 96%, and 96%, respectively, which are similar to those of carcinoembryonic antigen and claudin-4, and better than those of thyroid transcription factor-1, napsin-A, and mucin 4.
MUC21 could be used as an additional, novel, negative immunohistochemical marker to differentiate mesothelioma from lung adenocarcinoma. This article is protected by copyright. All rights reserved.